肿瘤细胞治疗研究
英文原题：The onco-embryonic antigen ROR1 is a target of chimeric antigen T cells for colorectal cancer.
The onco-embryonic antigen ROR1 is a target of chimeric antigen T cells for colorectal cancer.
结直肠癌的发病率和死亡率均位居全球第二。
结直肠癌在全球癌症发病率和死亡率中均居第二位。该病常在中晚期才被诊断，易发生转移、预后较差，且术后生活质量显著下降。ROR1是一种优良的胚胎性肿瘤抗原，也是多种肿瘤免疫疗法的靶点；此外，ROR1在结直肠癌中过表达。为填补靶向ROR1的CAR-T免疫疗法在结直肠癌治疗中的空白，研究人员设计并制备了抗ROR1 CAR-T细胞。该第三代CAR-T细胞可在体外和体内有效抑制结直肠癌生长。
Colorectal cancer is globally ranked second in both incidence and mortality rate. It usually develops during the middle or late stages of diagnosis, and is characterized by easy metastasis, poor prognosis, and a significant decline in postoperative quality of life. ROR1 is an excellent oncoembryonic antigen in numerous immunotherapy treatments for tumors. Additionally, it is overexpressed in colorectal cancer. To fill the void in CRC treatment with ROR1 as a target of CAR-T immunotherapy, we designed and prepared antiROR1-CART. This third-generation CAR-T cell can effectively inhibit the growth of colorectal cancer in vitro and in vivo.
MEMBER ACCOUNT
登录成功会直接打开下一页。
